secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001193125-23-195560
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen raises $120M from institutions; UGN-102 Phase 3 trials meet endpoints
----------------------------------------------------------------------------

- $120M gross proceeds from private placement at $9.54/share led by RA Capital and Great Point Partners.
- ATLAS trial: UGN-102 reduced risk of recurrence/progression/death by 55% vs TURBT alone.
- ENVISION trial: 79.2% complete response rate at 3 months for UGN-102.
- Pre-funded warrants at $0.001/share, not expiring; closing expected July 28.
- NDA submission for UGN-102 anticipated in 2024 pending additional data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523195560/0001193125-23-195560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523195560/d538950d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-195560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer